Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Sees Significant Decrease in Short Interest

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw a large decline in short interest in March. As of March 13th, there was short interest totaling 447,124 shares, a decline of 18.7% from the February 26th total of 549,755 shares. Based on an average trading volume of 296,385 shares, the short-interest ratio is currently 1.5 days. Approximately 0.5% of the company’s stock are sold short.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of IVA. Paradigm Biocapital Advisors LP purchased a new stake in shares of Inventiva during the fourth quarter worth approximately $18,600,000. ADAR1 Capital Management LLC purchased a new position in Inventiva in the 4th quarter valued at $12,601,000. Millennium Management LLC increased its stake in Inventiva by 2,267.7% in the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after buying an additional 2,540,540 shares during the period. UBS Group AG increased its stake in Inventiva by 28,881.6% in the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after buying an additional 2,634,580 shares during the period. Finally, SymBiosis Capital Partners LLC purchased a new position in Inventiva during the 4th quarter worth $12,090,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Stock Performance

Shares of IVA stock traded down $0.22 during mid-day trading on Wednesday, hitting $5.33. 233,046 shares of the stock were exchanged, compared to its average volume of 439,254. The stock’s fifty day simple moving average is $6.26 and its two-hundred day simple moving average is $5.37. Inventiva has a 12-month low of $2.85 and a 12-month high of $7.98.

Inventiva (NASDAQ:IVA) last announced its earnings results on Saturday, February 14th. The company reported ($0.16) EPS for the quarter. The firm had revenue of $0.01 million for the quarter. Analysts predict that Inventiva will post -2.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on IVA shares. UBS Group assumed coverage on shares of Inventiva in a report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Thursday, January 22nd. HC Wainwright set a $24.00 price target on Inventiva and gave the company a “buy” rating in a research note on Wednesday, January 28th. Truist Financial assumed coverage on Inventiva in a report on Thursday, March 19th. They set a “buy” rating and a $13.00 price target for the company. Finally, Barclays started coverage on Inventiva in a research report on Tuesday, January 27th. They set an “overweight” rating and a $18.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Inventiva has a consensus rating of “Buy” and an average price target of $16.56.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.